Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding increases in their shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than corporate financial performance.
| Transaction Type | Price | Date |
|---|---|---|
| Ordinary Shares Purchase | £12.43 per share | January 10, 2011 |
| Ordinary Share ADRs Purchase | $38.76 per ADR | January 6, 2011 |
Material Changes
The filing details an increase in share interests for specific individuals following the re-investment of dividends paid to shareholders on January 6, 2011. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- The filing reports share purchases by directors and connected persons, including Dr. M M Slaoui, Mr. J R Stéphenne, and Mr. D J Phelan, among others.
- Transactions were executed at £12.43 per Ordinary share and $38.76 per ADR.
- The purchases were funded through the re-investment of dividends paid on January 6, 2011.
- The Company was advised of these transactions on January 11, 2011.